Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Karyotyping

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Karyotyping. Displaying page 1 of 1.
    EudraCT Number: 2016-004946-27 Sponsor Protocol Number: E2020-A001-219 Start Date*: 2017-05-18
    Sponsor Name:Eisai Inc.
    Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D...
    Medical condition: Down Syndrome, Cognitive Dysfunction
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001005-82 Sponsor Protocol Number: TALL/IP/2 Start Date*: 2015-05-05
    Sponsor Name:Galileo Research Srl
    Full Title: Phase II trial of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with ovarian carcinoma with minimal or microscopic residual disease at second look laparotom...
    Medical condition: Ovarian carcinoma (FIGO stage IIIA and IIIB/IIIC/IV; patients with extra-abdominal disease will be excluded by the study unless those with pleural effusion) with minimal/microscopic residual disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005780-16 Sponsor Protocol Number: 1042_OPBG_2016 Start Date*: 2019-04-10
    Sponsor Name:IRCCS Bambino Gesù Children's Hospital
    Full Title: A phase 2 controlled study with blinded outcome assessment on the efficacy of Bumetanide vs no drug treatment for cognitive improvement to rescue cognitive functions in children and adolescents wit...
    Medical condition: Down Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021821-10 Sponsor Protocol Number: MSC_Apceth_001 Start Date*: 2011-01-21
    Sponsor Name:apceth GmbH & Co. KG
    Full Title: Open, Randomized, Mono-centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous In-fusion of Human Bone-Marrow Derived Autologous, CD34-...
    Medical condition: Critical Limb Ischemia in Patients with Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10066719 Peripheral arterial occlusive disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005047-26 Sponsor Protocol Number: CAMN107A2302 Start Date*: 2007-10-15
    Sponsor Name:Novartis Pharma Services
    Full Title: A phase III multi-center, open-label, randomized study of the efficacy of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+ ) chronic myelogenous leukemia in ...
    Medical condition: Nilotinib will be evaluated in patients having showed a suboptimal cytogenetic response to imatinib
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) ES (Completed) DE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007054-35 Sponsor Protocol Number: CAMN107A2404 Start Date*: 2009-08-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Medical condition: IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000944-26 Sponsor Protocol Number: HOVON 65 MM / GMMG-HD4 Start Date*: 2007-05-02
    Sponsor Name:HOVON foundation
    Full Title: A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenanc...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006446-33 Sponsor Protocol Number: CSTI571 basket 1 Start Date*: 2007-03-20
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: Open-label trial of Imatinib in patients with Desmoid Tumor and Chondrosarcoma
    Medical condition: Patients with Desmoid Tumor and Chondrosarcoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039491 Sarcoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001263-23 Sponsor Protocol Number: BP27832 Start Date*: 2014-03-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)
    Medical condition: Down Syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10044688 Trisomy 21 PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012083-14 Sponsor Protocol Number: EPC2008-02 Start Date*: 2009-06-17
    Sponsor Name:MEDA Pharma GmbH & Co. KG
    Full Title: An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene® (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin®), on I...
    Medical condition: Acute Myeloid Leukemia in First Complete Remission (CR1)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10000887 Acute myeloid leukemia in remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004644-70 Sponsor Protocol Number: Start Date*: 2010-11-22
    Sponsor Name:GOELAMS
    Full Title: Etude de phase III ouverte, randomisée portant sur l’intérêt d’un traitement d’entretien par rituximab en post-autogreffe dans le traitement des lymphomes à cellules du manteau chez des patients âg...
    Medical condition: Traitement d'entretien de patients porteur d'un lymphome du manteau en réponse.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006677-83 Sponsor Protocol Number: HuLuc63-1703 Start Date*: 2010-04-26
    Sponsor Name:AbbVie Biotherapeutics Inc. (AbbVie)
    Full Title: A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapse...
    Medical condition: Patients with relapsed multiple myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003737-15 Sponsor Protocol Number: ACE-CL-110 Start Date*: 2017-10-16
    Sponsor Name:Acerta Pharma BV
    Full Title: A Phase 1/2 Proof-of-Concept Study Investigating AZD6738 monotherapy and Acalabrutinib in Combination with AZD6738 (ATR inhibitor) in Subjects with Relapsed or Refractory High-risk Chronic Lymphocy...
    Medical condition: Relapsed or Refractory High-risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001151-68 Sponsor Protocol Number: TUD-APOLLO-064 Start Date*: 2016-05-19
    Sponsor Name:Technische Universität Dresden
    Full Title: A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diag...
    Medical condition: newly diagnosed high-risk acute promyelocytic leukemia (APL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001019 Acute promyelocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) NL (Prematurely Ended) BE (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 23:09:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA